Enamel matrix derivative proteins for the treatment of proximal class II furcation involvements: a prospective 24-month randomized clinical trial.
OBJECTIVE
This study aimed to evaluate the response of proximal furcations treated with enamel matrix derivative proteins (EMD) in a 24-month follow-up.


METHODS
Twelve patients presenting bilateral class II proximal furcation with vertical probing depth (PD) ≥5 mm and bleeding on probing were selected. The furcations were assigned to: a control group (n=12), open flap debridement (OFD)+EDTA and a test group (n=12) - OFD+EDTA+EMD. The gingival margin position, PD, relative vertical and horizontal clinical attachment level (RVCAL and RHCAL), vertical and horizontal bone level (VBL and HBL) and furcation closure were evaluated before treatment and after 6, 12 and 24 months.


RESULTS
After follow-up, no statistical difference could be seen between groups. At 24 months, the test group showed 1.9 ± 1.6 mm PD reduction whereas the control group showed 1.0 ± 1.3 mm PD reduction. RHCAL gains of the control and the test group were 0.7 ± 1.3 and 1.4 ± 0.9 mm, respectively. However, at 24 months, the test group only presented five remaining class II furcations versus 10 furcations in the control group (p<0.05).


CONCLUSIONS
It could be concluded that EMD therapy promoted a reduction in the number of proximal furcations presenting a diagnosis of class II after 24 months of treatment compared with OFD therapy.
Casarin
Renato Corrêa Viana
RC
Department of Prosthodontics and Periodontics, Division of Periodontics, School of Dentistry at Piracicaba, Campinas State University, São Paulo, Brazil.
Ribeiro
Erica Del Peloso
Edel P
Nociti
Francisco Humberto
FH
Sallum
Antônio Wilson
AW
Ambrosano
Gláucia Maria Bovi
GM
Sallum
Enilson Antônio
EA
Casati
Márcio Zaffalon
MZ
D000328:Adult; D016301:Alveolar Bone Loss / Q000601:surgery; D000539:Alveolar Process / Q000473:pathology; D001672:Biocompatible Materials / Q000627:therapeutic use*; D002614:Chelating Agents / Q000627:therapeutic use; D003646:Debridement; D003746:Dental Enamel Proteins / Q000627:therapeutic use*; D003774:Dental Plaque Index; D004311:Double-Blind Method; D004492:Edetic Acid / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D017823:Furcation Defects / Q000145:classification / Q000601:surgery*; D005881:Gingiva / Q000473:pathology; D005884:Gingival Hemorrhage / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D017622:Periodontal Attachment Loss / Q000601:surgery; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000601:surgery; D011446:Prospective Studies; D013524:Surgical Flaps; D014092:Tooth Root / Q000473:pathology; D016896:Treatment Outcome
D001672:Biocompatible Materials; D002614:Chelating Agents; D003746:Dental Enamel Proteins; C109069:enamel matrix proteins; D004492:Edetic Acid